Drug Trial Radar · NCT07726992
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Aug 25, 2026
Primary completion
Dec 2029
Study completion Aug 2030
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with high-risk BCG-naive Papillary-Only non-muscle-invasive bladder cancer (NMIBC)
Conditions
- Papillary-Only Non-muscle-invasive Bladder Cancer
Interventions
SHR-1501+BCGDrug
SHR-1501+BCG
Placebo +BCGDrug
Placebo +BCG
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) assessed by BICR: Disease-free survival is defined as the time from randomization to date of DFS event assessed by BICR.Time frame: Up to approximately 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Medical Center of the Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.